Natera rises after EU certification for cancer test
BUZZ-Natera rises after EU certification for cancer test ** Shares of genetic testing firm Natera NTRA.O rise 2.7% to $281.85
** Co says its personalized cancer test, Signatera, received certification under the European Union's diagnostic device rules
** Signatera is used to detect traces of cancer that may remain after treatment and monitor for recurrence
** Co says Signatera is the first personalized residual-disease test for solid tumors to receive this EU certification
** Certification covers use across several cancers, including gastrointestinal, lung, breast, skin, gynecological and some blood cancers - NTRA
** NTRA says the certification will help it continue offering Signatera to EU patients after the 2028 regulatory transition deadline and reduce hurdles for launching new clinical trials
** Including session's move, NTRA up 22% YTD
(Reporting by Kunal Das in Bengaluru)
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers